References of "Coucke, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrognostic Factors in Urothelial Renal Pelvis and Ureter Tumours: a Multicentre Rare Cancer Network Study
Ozsahin, M; Zouhair, A; Villa, S et al

in European Journal of Cancer & Clinical Oncology (1999), 35/5

To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter ... [more ▼]

To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter was collected in a retrospective multicentre study. 12 patients with distant metastases were excluded from the statistical evaluation. All but 3 patients underwent radical surgery: nephroureterectomy (n = 71), nephroureterectomy and lymphadenectomy (n = 20), nephroureterectomy and partial bladder resection or transurethral resection (n =20), nephrectomy (n =10), and ureterectomy (n = 5). Sixty-one per cent (n = 77) of the tumours were located in the renal pelvis, and 21% (n = 27) in the ureter (both in 22 [17%]). Following surgery, residual tumour was still present in 33 patients (16 microscopic and 17 macroscopic). Postoperative radiotherapy was given to 45 (36%) patients. The median follow-up period was 39 months. In a median period of 9months, 66% of the patients relapsed (34 local, 7 locoregional, 16 regional, and 24 distant). The 5- and 10-year survival were 29% and 19%, respectively, in all patients. In univariate analyses, statistically signi®cant factors in¯uencing the outcome were Karnofsky index, pT-classi®cation, pN-classi®cation, tumour localisation, grade, and residual tumour after surgery. Multivariate analysis revealed that independent prognostic factors in¯uencing outcome were pTclassi ®cation, the existence of residual tumour, and tumour localisation. In patients with urothelial renal pelvis and/or ureter tumours, a radical surgical attitude is mandatory; and the presence of tumour in the ureter is associated with a poorer prognosis. # 1999 Elsevier Science Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailRadiothérapie externe ou anti-inflammatoire non-stéroïdien pour la prévention des ossifications hétérotopiques après prothèse totale de hanche?
Zouhair, A; Ozsahin, M; Mouhsine, E et al

in Schweizerische Medizinische Wochenschrift (1999), 129(9), 370-376

External radiotherapy or non-steroid antiinflammatory drugs for prevention of heterotopic ossification following total hip replacement Heterotopic ossification (HO) is defined as the development of ... [more ▼]

External radiotherapy or non-steroid antiinflammatory drugs for prevention of heterotopic ossification following total hip replacement Heterotopic ossification (HO) is defined as the development of abnormal ossification in soft tissues. HO is a common disease after total hip replacement. Many therapeutic modalities have been proposed to prevent HO. The most commonly used modalities are nonsteroidal anti-inflammatory drugs (NSAID) or ionizing radiation administered just before or immediately after total hip replacement. As far as external radiation therapy is concerned, there are several published randomized studies aimed at investigating its efficacy and timing related to surgery, and at comparing ionizing irradiation to NSAID. In this article we review the published data in order to define guidelines which could be used in daily practice for the choice of prophylactic treatment against HO. [less ▲]

Detailed reference viewed: 126 (4 ULg)
Full Text
Peer Reviewed
See detailThe value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer : a multicenter analysis.
Begg, A-C; Hart, AAM; Dische, S et al

in Radiotherapy & Oncology (1999), 50

Purpose: The aim of this study was to assess the potential of pre-treatment cell kinetic parameters to predict outcome in head and neck cancer patients treated by conventional radiotherapy. Materials and ... [more ▼]

Purpose: The aim of this study was to assess the potential of pre-treatment cell kinetic parameters to predict outcome in head and neck cancer patients treated by conventional radiotherapy. Materials and methods: Data from 11 different centers were pooled. Inclusion criteria were such that the patients received radiotherapy alone, and that the radiotherapy was given in an overall time of at least 6 weeks with a dose of at least 60 Gy. All patients received a tracer dose of either iododeoxyuridine (IdUrd) or bromodeoxyuridine (BrdUrd) intravenously prior to treatment and a tumor biopsy was taken several hours later. The cell kinetic parameters labeling index (LI), DNA synthesis time (Ts) and potential doubling time (Tpot) were subsequently calculated from flow cytometry data, obtained on the biopsies using antibodies against I/BrdUrd incorporated into DNA. Each center carried out their own flow cytometry analysis. Results: From the 11 centers, a total of 476 patients conforming to the inclusion criteria were analyzed. Median values for overall time and total dose were 49 days and 69 Gy, respectively. Fifty one percent of patients had local recurrences and 53% patients had died, the majority from their disease. Median follow-up was 20 months; being 30 months for surviving patients. Multivariate analysis revealed that T-stage, maximum tumor diameter, differentiation grade, N-stage, tumor localization and overall time correlated with locoregional control, in decreasing order of significance. For the cell kinetic parameters, univariate analysis showed that only LI was significantly associated with local control (P=0.02), with higher values correlating with a worse outcome. Ts showed some evidence that patients with longer values did worse, but this was not significant (P=0.06). Tpot showed no trend (P=0.8). When assessing survival in a univariate analysis, neither LI nor Tpot associated with outcome (P=0.4, 0.4, respectively). Surprisingly, Ts did correlate with survival, with longer values being worse (P=0.02). In the multivariate analysis of local control, LI lost its significance (P=0.16). Conclusions: The only pretreatment kinetic parameter for which some evidence was found for an association with local control (the best end-point for testing the present hypothesis) was LI, not Tpot, and this evidence disappeared in a multivariate analysis. It therefore appears that pretreatment cell kinetic measurements carried out using flow cytometry, only provide a relatively weak predictor of outcome after radiotherapy in head and neck cancer. [less ▲]

Detailed reference viewed: 16 (7 ULg)
Full Text
Peer Reviewed
See detailReproducibility of measurements of potential doubling time of tumor cells in the multicenter NCI protocol T92-0045
Wilson, G-D; Paschoud, N; Pavy, J-J et al

in British Journal of Cancer (1999), 79(2), 323-332

Summary We compared the flow cytometric measurement and analysis of the potential doubling time ( Tpot) between three centres involved in the National Cancer Institute (NCI) protocol T92-0045. The primary ... [more ▼]

Summary We compared the flow cytometric measurement and analysis of the potential doubling time ( Tpot) between three centres involved in the National Cancer Institute (NCI) protocol T92-0045. The primary purpose was to understand and minimize the variation within the measurement. A total of 102 specimens were selected at random from patients entered into the trial. Samples were prepared, stained, run and analysed in each centre and a single set of data analysed by all three centres. Analysis of the disc data set revealed that the measurement of labelling index (LI) was robust and reproducible. The estimation of duration of S-phase ( Ts) was subject to errors of profile interpretation, particularly DNA ploidy status, and analysis. The LI dominated the variation in Tpot such that the level of final agreement, after removal of outliers and ploidy agreement, reached correlation coefficients of 0.9. The sample data showed poor agreement within each of the components of the measurement. There was some improvement when ploidy was in agreement, but correlation coefficients failed to exceed values of 0.5 for Tpot. The data suggest that observer-associated analysis of Ts and tissue processing and tumour heterogeneity were the major causes of variability in the Tpot measurement. The first two aspects can be standardized and minimized, but heterogeneity will remain a problem with biopsy techniques. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailPotentiation of cytotoxicity and radiosensitization of (E)-2'-deoxy-2' (fluoromethylene) cytidine by pentoxifylline in vitro.
LI, Y-X; Sun, L-Q; Paschoud, N et al

in International Journal of Cancer = Journal International du Cancer (1999), 80

(E)-28-deoxy-28-(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide-diphosphate reductase, has been shown to have anti-tumor activity against solid tumors and sensitize tumor cells to ... [more ▼]

(E)-28-deoxy-28-(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide-diphosphate reductase, has been shown to have anti-tumor activity against solid tumors and sensitize tumor cells to ionizing radiation. Pentoxifylline (PTX) can potentiate the cell killing induced by DNAdamaging agents through abrogation of DNA-damagedependent G2 checkpoint. We investigated the cytotoxic, radiosensitizing and cell-cycle effects of FMdC and PTX in a human colon-cancer cell line WiDr. PTX at 0.25–1.0 mM enhanced the cytotoxicity of FMdC and lowered the IC50 of FMdC from 79 6 0.1 to 31.2 6 2.1 nM, as determined by MTT assay. Using clonogenic assay, pre-irradiation exposure of exponentially growing WiDr cells to 30 nM FMdC for 48 hr or post-irradiation to 0.5 to 1.0 mM PTX alone resulted in an increase in radiation-induced cytotoxicity. Moreover, there was a significant change of the radiosensitization if both drugs were combined as compared with the effect of either drug alone. Cell-cycle analysis showed that treatment with nanomolar FMdC resulted in S-phase accumulation and that such an S-phase arrest can be abrogated by PTX. Treatment with FMdC prior to radiation increased post-irradiation-induced G2 arrest, and such G2 accumulation was also abrogated by PTX. These results suggest that pharmacological abrogation of S and G2 checkpoints by PTX may provide an effective strategy for enhancing the cytotoxic and radiosensitizing effects of FMdC. Int. J. Cancer 80:155–160, 1999. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailOncologie gastro-intestinale
Coucke, Philippe ULg; FREI; FELLEY et al

in Médecine et Hygiène (1999), 57(2240), 213-217

Même si aucune acquisition nouvelle n'est venue embaumer l'atmosphère encore trop souvent grisâtre de l'oncologie gastro-intestinale en 1998, la nécessité d'un consilium préthérapeutique associant ... [more ▼]

Même si aucune acquisition nouvelle n'est venue embaumer l'atmosphère encore trop souvent grisâtre de l'oncologie gastro-intestinale en 1998, la nécessité d'un consilium préthérapeutique associant chirurgiens, endoscopeurs, oncologues et radio-oncologues s'impose avec encore plus de fermeté, pour tous les cancers digestifs. Les patients devraient autant que possible être inclus dans des protocoles d'études bien conduits et bénéficier d'une chirurgie oncologique optimale. [less ▲]

Detailed reference viewed: 36 (2 ULg)
Full Text
Peer Reviewed
See detailFocalized external radiotherapy for resected solitary brain metastasis: does the dogma stand?
Coucke, Philippe ULg; Zouhair, Abderrahim; Ozsahin, Mahmut et al

in Radiotherapy & Oncology (1998), 47(1), 99-101

To investigate whether whole brain irradiation might be replaced by focalized irradiation after resection of a single brain metastasis in patients where extracranial tumor control is deemed to be obtained ... [more ▼]

To investigate whether whole brain irradiation might be replaced by focalized irradiation after resection of a single brain metastasis in patients where extracranial tumor control is deemed to be obtained. Patients and methods: Twelve patients were introduced in a phase I/II prospective study of conformal postoperative external irradiation after resection of a solitary brain metastasis. The radiation treatment consisted of 50.4 Gy (1.8 Gy per fraction, five fractions per week). The planning target volume consisted of the tumor bed and a 2 cm safety margin. All treatments were optimized with head immobilization, dedicated tomodensitometry and computer assisted three-dimensional treatment planning. Results: The median survival was 7.2 months (range 2.4–50.4 months). Eleven of the 12 patients died. Eight of the 12 patients presented intracranial recurrence and seven died as a consequence of intracranial tumor progression. Conclusions: Focalized external irradiation cannot serve as a reasonable alternative to whole brain radiotherapy (WBRT) even for patients with apparently one single resected brain metastasis. The dogma of ‘one metastasis=multiple metastases' seems to be confirmed. [less ▲]

Detailed reference viewed: 22 (1 ULg)
Full Text
See detaila new methylxanthine lisofylline increases radiosensitivity in air and hypoxia
Coucke, Philippe ULg; Crompton; Greiner et al

Scientific conference (1998, March 04)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailradiosensitizers FMdC and idUrd: HPLC-analysis in vitro
COUCKE, Philippe ULg; Cottin, E; Chen, X et al

in Radiotherapy & Oncology (1998), 48(Supp 1),

Detailed reference viewed: 7 (0 ULg)
See detailProfils apoptotiques altérés chez les patients irradiés montrant une hypersensibilité
Ozsahim, M; Mirabell, R; Emery, G-C et al

Conference (1998)

Detailed reference viewed: 7 (0 ULg)
See detailA case of spermatic cord liposarcoma
Zouhair, A; Ozsahin, M; Monney, M et al

Conference (1998)

Detailed reference viewed: 13 (0 ULg)
See detailSystemic capillary leak syndrome and localized breast cancer: a treatment dilemma
Monney, M; Pica, A; Spertini, F et al

Conference (1998)

Detailed reference viewed: 12 (0 ULg)
See detailWhen thyroid cell meet colon cells: the history of a tumor collision resulting in coexistence
Bosman, F-T; Jeanneret, W; Monney, M et al

Conference (1998)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detail(E)-2'-Deoxy-2'-(Fluoromethylene)cytidine potentiates radioresponse of two human solid tumor xenografts.
Sun, L-Q; Li, Y-X; Guillou, L et al

in Proceedings of the American Association for Cancer Research (1998)

Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide reducÃase, were evaluated on nude mice bearing s.c. human C33-A cervix ... [more ▼]

Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide reducÃase, were evaluated on nude mice bearing s.c. human C33-A cervix cancer and I -H7 MG glioblastoma xenografts. FMdC given once daily has a dosedependent antitumor effect. The maximum tolerated dose in the mice was reached with 10 daily i.p. administrations of 10 mg/kg over 12 days. In the case of radiotherapy (RT) alone (10 fractions over 12 days), the radiation dose required to produce local tumor control in 50% of the treated C33-A xenografts was 51.0 Gy. When combined with FMdC, the radiation dose required to produce local tumor control was reduced to 41.4 and 38.2 Gy, at respective doses of 5 and 10 mg/kg given i.p. l h before each irradiation. The corresponding enhancement ratios (ERs) were 1.2 and 1.3, respec tively. In U-87 MG xenografts, when 5-20 mg/kg FMdC combined with 30 or 40 Gy of RT, the combination treatment produced a significantly increased growth delay as compared with RT alone (P £0.002). The ERs of 5, 10, and 20 mg/kg FMdC at a dose of 30 Gy were 2.0, 1.4, and 1.8, respectively. At the 40-Gy level, ERs of 10 and 20 mg/kg FMdC were 1.4 and 1.7. When FMdC was combined with 50 Gy of RT, an increased long-term remission rate of 80-88.9% was observed, as compared with 25% for RT alone (P <0.05). FMdC produced moderate myelosuppression in the mice bearing cervix cancer, whereas leukocytosis occurred in the mice bearing glioblastoma at a low dose. Slightly increased skin toxicity (only with U-87 MG tumor) was observed, as compared with RT alone. In conclusion, FMdC is a potent cytotoxic agent and able to modify the radiation response of C33-A and U-87 MG xenografts. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of pentoxifylline on radiation-induced G2-phase delay and radiosensitivity of human colon and cervical cancer cells.
Li, Y-X; Weber-Johnson, K; Sun, L-Q et al

in Radiation Research (1998), 149(4),

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPrimary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and role of radiotherapy and chemotherapy
Li, Y-X; COUCKE, Philippe ULg; Li, J-Y et al

in International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society (1998), 83(3), 449-456

BACKGROUND. This study was conducted to determine whether the paranasal extension of a primary non-Hodgkin’s lymphoma (NHL) of the nasal cavity has any deleterious effect on patient outcome. METHODS. One ... [more ▼]

BACKGROUND. This study was conducted to determine whether the paranasal extension of a primary non-Hodgkin’s lymphoma (NHL) of the nasal cavity has any deleterious effect on patient outcome. METHODS. One hundred and seventy-five patients with previously untreated nasal NHL were reviewed. There were 2 with low grade, 107 with intermediate grade, 17 with high grade, and 49 with unclassifiable lymphomas. In 48 cases the immunophenotype was available and 46 were T-cell lymphoma. According to the Ann Arbor system, there were 133 patients with Stage IE, 28 with Stage IIE, 4 with Stage IIIE, and 10 with Stage IVE lymphomas. Stage IE was subdivided into limited Stage IE (i.e., confined to the nasal cavity [67 patients]) or extensive Stage IE (i.e., presenting with extension beyond the nasal cavity [66 patients]). For patients with limited Stage IE disease the treatment of choice was radiotherapy with or without chemotherapy. In patients with extensive Stage IE disease, treatment was comprised of a combination of chemotherapy and radiotherapy or radiotherapy alone. For patients with a more advanced stage of disease (IIE–IVE), chemotherapy was an integral part of the treatment and was completed by irradiation, especially for patients with Stage IIE disease. RESULTS. The actuarial overall survival (OS) and disease free survival (DFS) rates at 5 years for the whole group were 65% and 57%, respectively. The 5-year OS and DFS rates were influenced by stage, with a gradual decrease from 75% and 68% for Stage IE disease to 35% and 28% for Stage IIE disease, and 31% and 19% for Stage IIIE/IVE disease. Patients with limited Stage IE disease survived significantly longer (90% 5-year OS) compared with those with extensive Stage IE disease (57% 5-year OS; P , 0.001). For 67 patients with limited Stage IE disease, the 5-year OS was 89% with radiotherapy alone and 92% with radiotherapy and chemotherapy, whereas for 66 patients with extensive Stage IE disease, the 5-year OS was 54% with radiotherapy and 58% with combined modality therapy or chemotherapy (P . 0.05). CONCLUSIONS. The prognosis of patients with primary NHL of the nasal cavity is stage dependent. In this large cohort of Stage IE patients, it was demonstrated that the paranasal local extension was a significant prognostic factor associated with poorer treatment outcome. The authors believe that Ann Arbor Stage IE should be subclassified further into limited and extensive Stage IE. The addition of chemotherapy did not appear to modify significantly the survival of patients with either limited or extensive Stage IE disease. The extranodal progression observed in patients with extensive Stage IE and Stage IIE-IVE disease clearly illustrates the need for improvement of systemic treatment. Cancer 1998;83:449–56. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailFocalized external radiotherapy for resected solitary brain metastasis: the dogma stands
Coucke, Philippe ULg; Zouhair, A; Ozsahin, M et al

in Radiotherapy & Oncology (1998), 47

Abstract Purpose: To investigate whether whole brain irradiation might be replaced by focalized irradiation after resection of a single brain metastasis in patients where extracranial tumor control is ... [more ▼]

Abstract Purpose: To investigate whether whole brain irradiation might be replaced by focalized irradiation after resection of a single brain metastasis in patients where extracranial tumor control is deemed to be obtained. Patients and methods: Twelve patients were introduced in a phase I/II prospective study of conformal postoperative external irradiation after resection of a solitary brain metastasis. The radiation treatment consisted of 50.4 Gy (1.8 Gy per fraction, five fractions per week). The planning target volume consisted of the tumor bed and a 2 cm safety margin. All treatments were optimized with head immobilization, dedicated tomodensitometry and computer assisted three-dimensional treatment planning. Results: The median survival was 7.2 months (range 2.4–50.4 months). Eleven of the 12 patients died. Eight of the 12 patients presented intracranial recurrence and seven died as a consequence of intracranial tumor progression. Conclusions: Focalized external irradiation cannot serve as a reasonable alternative to whole brain radiotherapy (WBRT) even for patients with apparently one single resected brain metastasis. The dogma of ‘one metastasis=multiple metastases' seems to be confirmed. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailRadiotherapy of choroidal metastases.
Rosset, A; Zografos, L; COUCKE, Philippe ULg et al

in Radiotherapy & Oncology (1998), 46(3), 263-268

Abstract Purpose: This retrospective study was undertaken to clarify the role of high energy external beam radiation therapy (EBRT) and to determine its safety and efficacy on local control and visual ... [more ▼]

Abstract Purpose: This retrospective study was undertaken to clarify the role of high energy external beam radiation therapy (EBRT) and to determine its safety and efficacy on local control and visual acuity in patients suffering from choroidal metastases (CM). Materials and methods: The records of 58 consecutive patients treated with EBRT between 1970 and 1993 were analyzed. The female to male ratio was 2.9 and the median age was 59 years (range 40–81 years). Thirty-six patients (62%) had unilateral CM and 22 patients had bilateral CM. The mean number of lesions per eye was two. Retinal detachment was present in 65% of cases. The primary tumour (PT) was breast carcinoma for 38 patients (75%), lung carcinoma for 10 patients (17%) and gastrointestinal, genitourinary or unknown PT for the remaining 10 patients. The median interval of time between the PT and the CM was 55 months (range 0–228 months). All patients were treated with megavoltage irradiation. The median prescribed dose was 35.5 Gy (range 20–53 Gy) normalized at a 2 Gy per fraction schedule with an a/b value of 10 Gy. Various techniques were used and whenever possible the lens was spared. Ten patients with unilateral disease were treated in both eyes. Results: The tumour response was slow. When assessed after 3 months or more, the complete response rate was 53% with significantly better results for doses higher than 35.5 Gy (72 versus 33%; P = 0.009). Visual acuity was improved or stabilized in 62% of patients, with also significantly better results when doses higher than 35.5 Gy (P = 0.014) were administered. Amongst 26 patients with unilateral CM who had no elective contralateral irradiation, three developed metastasis in the opposite eye versus none of the 10 patients who had bilateral irradiation. Five complications occurred (three cataracts, one retinopathy and one glaucoma). Conclusion: Radiation therapy is an efficient and safe palliative treatment for choroidal metastases and it helps the preservation of vision. Thus, there is a major impact on the quality of life in a group of patients with an almost uniformly fatal prognosis. Both tumour response and visual acuity are significantly improved if doses higher than 35.5 Gy are administered. Whenever possible, a lens sparing technique should be used. Ó 1998 Elsevier Science Ireland Ltd. [less ▲]

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailLes chimioradiothérapies dans les cancers du col utérin
Maingon, P; COUCKE, Philippe ULg; Haie-Meder, C et al

in Cancer Radiotherapie (1998), 2

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailSilicone tissue-expander prosthesis (STEP) to protect the small bowel during radiation therapy for uterine malignancies.
Zouhair, A; Delaloye, J-F; Ozsahin, M et al

in Radiotherapy & Oncology (1998), 48(Supp1), 103

Detailed reference viewed: 8 (0 ULg)